Get the Stockscreener App
0.00
100.00%
-1.74
Lava Therapeutics Nv stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
LAVA Therapeutics NV isa clinical stage immuno-oncology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer. Company's pipeline include's products such as LAVA-1266, LAVA-1427, LAVA-1433, LAVA-1207, PF08046052, JNJ89853413.
See More
Previous Close:
$1.74
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$45.77M
Revenue:
$4.99M
Net Income/Loss:
$-28.29M
P/E Ratio:
0.00
EPS:
-1.0528
Net Cash Flow:
$-36.20M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$1.825
Lava Therapeutics Nv Stock (LVTX) Company Profile
Name
Lava Therapeutics Nv
Sector
Industry
Phone
31 6 3000 3035
Address
YALELAAN 62, UTRECHT
Compare LVTX vs VRTX, REGN, ARGX, ALNY, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LVTX
Lava Therapeutics Nv
|
0.00 | 45.77M | 4.99M | -28.29M | -36.20M | -1.0528 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Lava Therapeutics Nv Stock (LVTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-12-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-11-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Oct-25-22 | Initiated | H.C. Wainwright | Buy |
| Apr-19-21 | Initiated | JP Morgan | Overweight |
| Apr-19-21 | Initiated | Jefferies | Buy |
| Apr-19-21 | Initiated | SVB Leerink | Outperform |
View All
Lava Therapeutics Nv Stock (LVTX) Latest News
Growth Report: What is the Moat Score of LAVA Therapeutics NVMarket Risk Report & Daily Entry Point Alerts - baoquankhu1.vn
XOMA SEC FilingsXOMA Royalty Corporation 10-K, 10-Q, 8-K Forms - Stock Titan
AI Stocks: Can LAVA Therapeutics NV outperform in the next rally2026 Action & High Conviction Investment Ideas - baoquankhu1.vn
Published on: 2026-03-29 23:39:14 - baoquankhu1.vn
What is the Moat Score of LAVA Therapeutics NV2026 Momentum Check & Weekly High Return Opportunities - baoquankhu1.vn
Exit Recap: Does LAVA Therapeutics NV stock benefit from AI growth2026 Macro Impact & Daily Risk Controlled Trade Plans - baoquankhu1.vn
If You Invested $1,000 in LAVA Therapeutics N.V. (LVTX) - Stock Titan
Weekly Recap: Is LAVA Therapeutics NV currently under institutional pressureWeekly Profit Summary & AI Forecasted Entry/Exit Points - baoquankhu1.vn
Forecast Cut: Is LAVA Therapeutics NV currently under institutional pressurePortfolio Performance Summary & Daily Stock Trend Watchlist - baoquankhu1.vn
Risk Check: What is the Moat Score of LAVA Therapeutics NVCEO Change & Weekly Top Gainers Alerts - baoquankhu1.vn
Risk Check: How much upside does LAVA Therapeutics NV haveDay Trade & Free Growth Oriented Trading Recommendations - baoquankhu1.vn
LVTX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
AI Stocks: What is the Moat Score of LAVA Therapeutics NVJuly 2025 PreEarnings & Free Real-Time Market Sentiment Alerts - baoquankhu1.vn
Portfolio Update: Is LAVA Therapeutics NV benefiting from innovation trendsJuly 2025 Momentum & AI Enhanced Market Trend Forecasts - baoquankhu1.vn
What is LAVA Therapeutics N.V.’s book value per share2025 Earnings Surprises & Verified Momentum Stock Alerts - mfd.ru
How LAVA Therapeutics N.V. (4PKB) stock reacts to fiscal policiesChart Signals & Safe Entry Trade Reports - mfd.ru
Is LAVA Therapeutics N.V. stock a good choice for value investorsJuly 2025 Fed Impact & Verified Chart Pattern Signals - mfd.ru
What dividend growth rate does LAVA Therapeutics N.V. offerRecession Risk & Technical Pattern Based Buy Signals - mfd.ru
Can LAVA Therapeutics N.V. outperform in the next rallyJuly 2025 Catalysts & Safe Entry Zone Tips - mfd.ru
What’s the fair value of LAVA Therapeutics N.V. stockWeekly Trade Report & Capital Protection Trading Alerts - mfd.ru
Generation Bio investors cashed out at $4.2913 a share in XOMA takeover - Stock Titan
LAVA Therapeutics Approves Merger with New Topco B.V. - MSN
Risk Off: Does LAVA Therapeutics NV stock benefit from AI growth2025 Geopolitical Influence & AI Based Trade Execution Alerts - baoquankhu1.vn
Market Rankings: What is the Moat Score of LAVA Therapeutics NVJuly 2025 Pullbacks & Free Safe Entry Trade Signal Reports - baoquankhu1.vn
Is LAVA Therapeutics N.V. stock a buy before product launchesBlue Chip Stock Analysis & Minimal Capital Trading Plans - Bollywood Helpline
Will LAVA Therapeutics N.V. stock reach all time highs in 2025July 2025 Highlights & Reliable Volume Spike Alerts - Bollywood Helpline
Market Recap: Is LAVA Therapeutics NV forming a double bottomStock Surge & Fast Exit/Entry Strategy Plans - baoquankhu1.vn
Moving Averages: How LAVA Therapeutics NV stock reacts to inflationary pressuresBreakout Watch & Daily Profit Focused Stock Screening - Bộ Nội Vụ
Biotech royalty firm XOMA shifts finance leadership after nearly 20 years - Stock Titan
Is LAVA Therapeutics N.V. stock recession proofWeekly Gains Summary & Consistent Profit Trade Alerts - Улправда
Can LAVA Therapeutics N.V. stock hit record highs againJuly 2025 Institutional & Low Risk High Win Rate Stock Picks - Улправда
XOMA Royalty Announces Dual Acquisitions of HilleVax and LAVA Therapeutics - MSN
What analysts say about LAVA Therapeutics NV 4PKB stockEarnings Forecast Updates & Free Dynamic Capital Growth - earlytimes.in
Drug royalties reshuffled as XOMA trades part of one for nine experimental drugs - Stock Titan
HC Wainwright & Co. Downgrades LAVA Therapeutics N.V. (LVTX) - MSN
Will LAVA Therapeutics N.V. stock see insider buyingJuly 2025 Patterns & High Conviction Investment Ideas - Улправда
Published on: 2025-12-20 11:31:17 - Улправда
Is LAVA Therapeutics N.V. (4PKB) stock worth buying before Fed actionMarket Sentiment Report & Comprehensive Market Scan Reports - DonanımHaber
How dovish Fed policy supports LAVA Therapeutics N.V. (4PKB) stockOptions Play & Weekly Watchlist for Hot Stocks - DonanımHaber
How LAVA Therapeutics N.V. stock reacts to job market data2025 Sector Review & AI Enhanced Trading Alerts - Улправда
Is LAVA Therapeutics N.V. (4PKB) stock dividend growth reliableMarket Volume Summary & Momentum Based Trading Ideas - Улправда
Published on: 2025-12-18 13:21:42 - Улправда
Volume Recap: Is LAVA Therapeutics NV 4PKB stock worth buying before Fed actionAnalyst Downgrade & Short-Term Trading Opportunity Alerts - moha.gov.vn
LAVA Therapeutics N.V. (NASDAQ:LVTX) Given Consensus Recommendation of “Reduce” by Analysts - Defense World
Xoma Royalty Expands Portfolio Through Mural Oncology Acquisition - AD HOC NEWS
XOMA Royalty (Nasdaq: XOMA) completes $2.035 per share Mural Oncology takeover - stocktitan.net
Total debt per share of LAVA Therapeutics NV – BER:4PKB - TradingView
Operating cash flow per share of LAVA Therapeutics NV – SWB:4PKB - TradingView
Can LAVA Therapeutics N.V. (4PKB) stock expand revenue streamsMarket Activity Recap & Daily Volume Surge Signals - Newser
Why LAVA Therapeutics N.V. (4PKB) stock is listed among top recommendations2025 Growth vs Value & Daily Stock Trend Reports - Newser
Is LAVA Therapeutics NV overvalued or undervalued? - Markets Mojo
Lava Therapeutics Nv Stock (LVTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.49%
1.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):